Tevogen Bio Holdings Inc (TVGN)

$0.67 -0.11 (-13.54%)
Market Cap 132.56M
Revenue (ttm) 0.00
Net Income (ttm) -13.73M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -0.46
Volume 1,760,200
Avg Vol 910,894
Day's Range N/A - N/A
Shares Out 196.71M
Stochastic %K 10%
Beta -0.83
Analysts Strong Sell
Price Target $10.00

Company Profile

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 pati...

Industry: Biotechnology
Sector: Healthcare
Phone: 877 838 6436
Website: tevogen.com
Address:
15 Independence Boulevard, Suite #410, Warren, United States
DevIli
DevIli Oct. 4 at 5:41 AM
$TVGN still buying
0 · Reply
robsmi63
robsmi63 Oct. 3 at 11:13 PM
$TVGN where is everyone going? But... But... But, they said 10billion. Come back
4 · Reply
bekie1985
bekie1985 Oct. 3 at 8:02 PM
$TVGN added at .69 and holding a big stack of shares right now. Will keep adding if it should dip lower. I stil believe 😎💯😎💯💯
0 · Reply
jeroen2505
jeroen2505 Oct. 3 at 7:57 PM
$TVGN out, this is going to be a bloodbath
1 · Reply
stayskuntin11
stayskuntin11 Oct. 3 at 7:24 PM
$TVGN whatis going on this is criminal
0 · Reply
jn_svoboda
jn_svoboda Oct. 3 at 6:02 PM
$TVGN This is totally bearish now. Still the Tevogen company has a huge potential ahead. Therefore, I keep holding. 😉
0 · Reply
CulinaryCapitalist
CulinaryCapitalist Oct. 3 at 4:31 PM
$TVGN
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:59 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $HSDT $BFRI $DOGZ $TC $TVGN news
0 · Reply
EUROPEANIMAL
EUROPEANIMAL Oct. 2 at 6:14 PM
$TVGN going to 0,6
0 · Reply
stayskuntin11
stayskuntin11 Oct. 2 at 6:03 PM
$TVGN will we ever get above $1
0 · Reply
Latest News on TVGN
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Sep 25, 2025, 8:30 AM EDT - 9 days ago

Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Sep 23, 2025, 8:30 AM EDT - 11 days ago

Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Sep 19, 2025, 3:40 PM EDT - 15 days ago

Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489's Potential Impact for 20 Million Americans

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Sep 10, 2025, 11:59 AM EDT - 24 days ago

Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Sep 9, 2025, 3:15 PM EDT - 25 days ago

Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Sep 8, 2025, 9:27 AM EDT - 26 days ago

Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Sep 4, 2025, 3:48 PM EDT - 4 weeks ago

Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Sep 3, 2025, 4:15 PM EDT - 4 weeks ago

Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Aug 27, 2025, 3:20 PM EDT - 5 weeks ago

Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Aug 26, 2025, 2:50 PM EDT - 5 weeks ago

Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company's Mission of Health Equity

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Aug 25, 2025, 3:10 PM EDT - 5 weeks ago

Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

Aug 22, 2025, 3:25 PM EDT - 6 weeks ago

Tevogen Recognized in BINJE's BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Aug 19, 2025, 3:40 PM EDT - 6 weeks ago

REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Aug 19, 2025, 12:10 PM EDT - 6 weeks ago

Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Aug 18, 2025, 5:50 PM EDT - 6 weeks ago

Tevogen CEO Donates Personal Shares to Support Local Law Enforcement

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Aug 18, 2025, 5:15 PM EDT - 6 weeks ago

Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Aug 14, 2025, 3:55 PM EDT - 7 weeks ago

Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 13, 2025, 3:53 PM EDT - 7 weeks ago

Repeat - Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

Aug 11, 2025, 3:45 PM EDT - 7 weeks ago

Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Aug 11, 2025, 1:24 PM EDT - 7 weeks ago

REPEAT -- Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion and $22 Billion

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

Aug 11, 2025, 11:58 AM EDT - 7 weeks ago

Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to Follow

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 11, 2025, 9:28 AM EDT - 7 weeks ago

REPEAT - Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 8, 2025, 11:37 AM EDT - 2 months ago

REPEAT - Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Aug 7, 2025, 9:00 AM EDT - 2 months ago

Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Aug 6, 2025, 3:59 PM EDT - 2 months ago

Tevogen Sees Significant Institutional Ownership Growth; 73% of Holders Increase Positions

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Aug 5, 2025, 2:32 PM EDT - 2 months ago

Tevogen.AI Expands Collaboration With Databricks and Microsoft to Build the Beta Version of Its PredicTcell™ Model With a Focus on Oncology

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Aug 1, 2025, 3:57 PM EDT - 2 months ago

Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

Aug 1, 2025, 3:30 PM EDT - 2 months ago

Tevogen Bio to Accept $1 Million Additional Grant Funding for AI Expansion

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Jul 30, 2025, 12:41 PM EDT - 2 months ago

Tevogen Highlights 74% Insider Ownership, Reinforcing Long-Term Vision

Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Jul 28, 2025, 11:52 AM EDT - 2 months ago

Tevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Jul 18, 2025, 12:36 PM EDT - 2 months ago

Tevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active Peptides

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Jul 17, 2025, 9:15 AM EDT - 2 months ago

Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

Jul 16, 2025, 11:57 AM EDT - 2 months ago

Tevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha Launch

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Jul 14, 2025, 9:30 AM EDT - 2 months ago

Tevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development Costs

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Jul 10, 2025, 3:13 PM EDT - 3 months ago

Tevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate Innovation

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Jun 30, 2025, 2:28 PM EDT - 3 months ago

Tevogen CEO Contributes to Build-Out and First-Year Operations of New Headquarters

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Jun 18, 2025, 8:30 AM EDT - 3 months ago

Tevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target Discovery

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Jun 9, 2025, 9:00 AM EDT - 4 months ago

Tevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars Initiatives

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

May 30, 2025, 11:01 AM EDT - 4 months ago

Tevogen Details its Artificial Intelligence Initiative, Tevogen.AI; Proprietary AI-Powered Immunotherapy with Microsoft and Databricks Partnerships

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

May 23, 2025, 3:49 PM EDT - 4 months ago

Tevogen Bio Plans to Expand Specialty Care Pipeline to Include Patients 65+, Building on Previous Forecast of Nearly $1 Billion in Launch-Year; Updated rNPV to Follow

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

May 22, 2025, 1:21 PM EDT - 4 months ago

Tevogen to Update on Robust Portfolio Assets, Business Expansion, Partnerships, Limited Tradable Float, High Insider Ownership and Strong Investor Confidence Ahead of June 23 Annual Meeting

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025, 8:00 AM EDT - 5 months ago

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025, 3:45 PM EDT - 5 months ago

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Apr 30, 2025, 3:49 PM EDT - 5 months ago

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Apr 29, 2025, 1:48 PM EDT - 5 months ago

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Apr 29, 2025, 8:00 AM EDT - 5 months ago

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Apr 28, 2025, 4:36 PM EDT - 5 months ago

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

Tevogen Bio Announces 2025 Annual Meeting

Apr 25, 2025, 2:33 PM EDT - 5 months ago

Tevogen Bio Announces 2025 Annual Meeting

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Apr 17, 2025, 2:54 PM EDT - 6 months ago

Tevogen Bio Finalizes Agreement for Company's Own Cell Therapy Production Facility

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

Apr 15, 2025, 2:03 PM EDT - 6 months ago

Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

DevIli
DevIli Oct. 4 at 5:41 AM
$TVGN still buying
0 · Reply
robsmi63
robsmi63 Oct. 3 at 11:13 PM
$TVGN where is everyone going? But... But... But, they said 10billion. Come back
4 · Reply
bekie1985
bekie1985 Oct. 3 at 8:02 PM
$TVGN added at .69 and holding a big stack of shares right now. Will keep adding if it should dip lower. I stil believe 😎💯😎💯💯
0 · Reply
jeroen2505
jeroen2505 Oct. 3 at 7:57 PM
$TVGN out, this is going to be a bloodbath
1 · Reply
stayskuntin11
stayskuntin11 Oct. 3 at 7:24 PM
$TVGN whatis going on this is criminal
0 · Reply
jn_svoboda
jn_svoboda Oct. 3 at 6:02 PM
$TVGN This is totally bearish now. Still the Tevogen company has a huge potential ahead. Therefore, I keep holding. 😉
0 · Reply
CulinaryCapitalist
CulinaryCapitalist Oct. 3 at 4:31 PM
$TVGN
0 · Reply
HouseOfTheDragons
HouseOfTheDragons Oct. 3 at 2:59 AM
Looks like volume & momentum could be shifting in to ASTC! Tiny float getting a lot of attention and could explode upwards on volume. Watchers on ASTC are growing very fast and it could be the potential top runner for this week! Starting its 300% run - keep it on watch! Also watching for breakout: $HSDT $BFRI $DOGZ $TC $TVGN news
0 · Reply
EUROPEANIMAL
EUROPEANIMAL Oct. 2 at 6:14 PM
$TVGN going to 0,6
0 · Reply
stayskuntin11
stayskuntin11 Oct. 2 at 6:03 PM
$TVGN will we ever get above $1
0 · Reply
Teo_j
Teo_j Oct. 2 at 10:19 AM
$TVGN looks dead
0 · Reply
EUROPEANIMAL
EUROPEANIMAL Oct. 1 at 5:33 PM
$TVGN FDA affectet by shut down, delaying .......
0 · Reply
EUROPEANIMAL
EUROPEANIMAL Sep. 30 at 4:34 PM
$TVGN 0,5 to 0,6 rang.
0 · Reply
mscp
mscp Sep. 30 at 12:13 AM
$TVGN this thing is stuck lol
0 · Reply
GfromTn
GfromTn Sep. 29 at 11:25 PM
$TVGN have they filled their dilution or atm or is there more dilution coming?? Are we looking at potential RS shoot me straight ??
0 · Reply
dcme010711
dcme010711 Sep. 29 at 9:34 PM
$TVGN
0 · Reply
LegendaryCharts
LegendaryCharts Sep. 28 at 12:48 PM
$PAVS Ultra low float is getting squeezed now, Could see a nice move to 2$+ here tomorrow $PSQH Crypto tresuary launched $TVGN 100x PredicTcell™ Beta Data Expansion $PSTV 5$ price target mantained
0 · Reply
Tariq_j
Tariq_j Sep. 26 at 11:05 PM
$TVGN
1 · Reply
EUROPEANIMAL
EUROPEANIMAL Sep. 26 at 6:34 PM
$TVGN then we need more dates ... If no then holdrrs losing confidence ....
0 · Reply
EUROPEANIMAL
EUROPEANIMAL Sep. 26 at 1:40 PM
$TVGN Microsoft could buy stake in TVGN near 5%
0 · Reply
chris_stocks
chris_stocks Sep. 26 at 6:31 AM
$TVGN And yet none of that news is driving up the sp.
1 · Reply
auzzy
auzzy Sep. 25 at 1:38 PM
$TVGN
1 · Reply